This week in psychedelic business news: Cybin acquires a Phase…
In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Hello psychedelic investors! Today’s episode is a bit different yet still relevant to all of us invested in the psychedelic industry!
To summarize,
Andrew Yang comes out Hard against the war on drugs and for legalizing psilocybin. He says “The war on drugs has been a war on people”.
Specifically, Andrew Yang calls out the criminalization of opioid use, saying big pharma has gotten these people addicted while “generating billions of dollars of blood money”, and then we throw people in jail for the pharma industries failures.
This is, in Yang’s eyes, not a criminal problem, but a public health problem.
If people are addicted to something, don’t throw them in jail, get them the help that they need to treat an illness that in many cases was caused by billionaire pharma companies.
How will Andrew Yang create a de facto decriminalization?
He would instruct the DA not to prosecute for possession charges.
Its that simple.
Finally he talks about how he is for the legalization of psilocybin and open to legalize other substances.
Yang is calling for decriminalizing the use of all drugs, AND to legalize psilocybin..
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
For any collaborations, you can reach us on our email
email: thepsychedelicinvestor@gmail.com
If you are thinking of joining Benzinga Pro, why not use our link, and we will both get a discount!
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#AndrewYang #AndrewYangMayor #AndrewYangDebate
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy
Steven’s consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.